US5469846A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Implantable non-enzymatic electrochemical glucose sensor
Assignee: Duquesne University of the Holy Spirit
•
Filing: 1994-09-27
•
Granted: 1995-11-28
•
Expires: 2014-09-27
Abstract
Abstract A non-enzymatic implantable blood glucose detector. The detector makes use of a non-reactive tin oxide semiconductor measurement electrode which is suitably energized by an electrical power source. Variations in current density at the measurement electrode are related to variations in glucose content of blood. The device also uses variable voltage to allow the electrode to be self-cleaning.
Inventors
- 👤 Shahed U. M. Khan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 23:08
CPC Classifications
A; A61; A61B; A61B5/00; A61B5/145; A61B5/14532; A61B5/1468; A61B5/1473; A61B5/48; A61B5/4836; A61B5/4839; A61M; A61M5/00; A61M5/14; A61M5/168; A61M5/172; A61M5/1723
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
127 words
A method of detecting changes in blood glucose levels, comprising: providing an implantable non-enzymatic blood glucose detector having a non-reactive semiconductor measurement electrode energized by a battery means and disposed within a sleeve member having an opening permitting glucose molecules to pass therethrough to said measurement electrode, but resisting the passage therethrough of molecules of predetermined greater size; connecting said measurement electrode to a monitoring means for monitoring a current density at said measurement electrode in response to glucose molecule oxidation or glucose molecule reduction reactions at said measurement electrode: continuously passing blood through said sleeve opening to said measurement electrode; continuously monitoring said current density by said monitoring means; and translating changes in current density detected by said monitoring means to changes in blood glucose levels.
Claim 2
Independent Claim
127 words
A method of detecting changes in blood glucose levels, comprising: providing an implantable non-enzymatic blood glucose detector having a non-reactive semiconductor measurement electrode energized by a battery means and disposed within a sleeve member having an opening permitting glucose molecules to pass therethrough to said measurement electrode, but resisting the passage therethrough of molecules of predetermined greater size; connecting said measurement electrode to a monitoring means for monitoring a current density at said measurement electrode in response to glucose molecule oxidation or glucose molecule reduction reactions at said measurement electrode: continuously passing blood through said sleeve opening to said measurement electrode; continuously monitoring said current density by said monitoring means; and translating changes in current density detected by said monitoring means to changes in blood glucose levels.
Claim 3
Dependent Claim
26 words
The method of claim 1 employing as material for said semiconductor measurement electrode a semiconductor selected from the group consisting of tin oxide and titanium dioxide.
Claim 4
Dependent Claim
36 words
The method of claim 2 employing said sleeve member opening covered with a biocompatible membrane sized to permit glucose molecules to pass therethrough, but to preclude passage therethrough of molecules sized greater than about 100,000 M.W.
Claim 5
Dependent Claim
36 words
The method of claim 1 employing as said sleeve member a venturi sleeve having a restricted opening for allowing said glucose molecules to pass therethrough, but precluding passage therethrough of molecules larger than about 100,000 M.W.
Claim 6
Dependent Claim
22 words
The method of claim 1 employing said battery means at a variable voltage, thereby maintaining said measurement electrode in a clean state.
Claim 7
Independent Claim
204 words
A method of delivering insulin within a patient comprising: providing an implantable non-enzymatic blood glucose unit comprising an implantable non-reactive semiconductor measurement electrode, said electrode energized by an electrical power source and disposed within a sleeve member having an opening permitting glucose molecules to pass therethrough to said measurement electrode, but precluding the passage therethrough of molecules sized greater than about 100,000 M.W., said unit further comprising monitoring means connected to said electrode for monitoring current density at said measurement electrode, said unit further including an insulin reservoir and insulin pump; implanting said unit in a patient; continuously passing blood from said patient through said sleeve opening to said measurement electrode; continuously monitoring changes in current density at said measurement electrode in response to glucose molecule oxidation or glucose molecule reduction reactions at said measurement electrode, with said monitoring means; translating changes in current density detected by said monitoring means to changes in blood glucose levels; and delivering insulin from said insulin reservoir to said patient via said insulin pump in response to changes in current density detected by said monitoring means in response to changes in blood glucose levels from a normal glucose level to a glucose level exceeding a predetermined set point.
Claim 8
Independent Claim
204 words
A method of delivering insulin within a patient comprising: providing an implantable non-enzymatic blood glucose unit comprising an implantable non-reactive semiconductor measurement electrode, said electrode energized by an electrical power source and disposed within a sleeve member having an opening permitting glucose molecules to pass therethrough to said measurement electrode, but precluding the passage therethrough of molecules sized greater than about 100,000 M.W., said unit further comprising monitoring means connected to said electrode for monitoring current density at said measurement electrode, said unit further including an insulin reservoir and insulin pump; implanting said unit in a patient; continuously passing blood from said patient through said sleeve opening to said measurement electrode; continuously monitoring changes in current density at said measurement electrode in response to glucose molecule oxidation or glucose molecule reduction reactions at said measurement electrode, with said monitoring means; translating changes in current density detected by said monitoring means to changes in blood glucose levels; and delivering insulin from said insulin reservoir to said patient via said insulin pump in response to changes in current density detected by said monitoring means in response to changes in blood glucose levels from a normal glucose level to a glucose level exceeding a predetermined set point.
Claim 9
Dependent Claim
14 words
The method of claim 6 employing as said electrical power source a battery means.
Claim 10
Dependent Claim
26 words
The method of claim 6 employing as a material for said semiconductor electrode a semiconductor selected from the group consisting of tin oxide and titanium dioxide.
Claim 11
Dependent Claim
36 words
The method of claim 8 employing said sleeve member opening covered with a biocompatible membrane sized to permit glucose molecules to pass therethrough, but to preclude passage therethrough of molecules sized greater than about 100,000 M.W.
Claim 12
Dependent Claim
37 words
The method of claim 8 employing as said sleeve member a venturi sleeve having a restricted opening for allowing said glucose molecules to pass therethrough, but precluding passage therethrough of molecules sized greater than about 100,000 M.W.
Claim 13
Dependent Claim
23 words
The method of claim 6 employing said electrical power source at a variable voltage, thereby maintaining said measurement electrode in a clean state.
Claim 14
Dependent Claim
63 words
The method of claim 6 further employing with said unit a glucose reservoir and glucose pump, said method including the step of delivering glucose to said patient via said glucose pump in response to current density changes detected by said monitoring means corresponding to changes in blood glucose levels from a normal glucose level to a glucose level below a predetermined set point.
References Cited (Backward Citations)
US3406109A
Cited
US4059406A
Cited
US4340458A
Cited
US4436094A
Cited
US4633878A
Cited
US4496454A
Cited
US4599157A
Cited
SU1281988A1
Cited
US4911794A
Cited
US4919141A
Cited
US4950378A
Cited
JPH02287145A
Cited
US5109850A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-11-27 | 1999-05-29 | 1999-11-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-11-27 | 2003-05-29 | 2003-11-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-11-27 | 2007-05-29 | 2007-11-28 | $7700.00 | Window Closed / Lapsed |